Mansoor Khan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8928156/publications.pdf

Version: 2024-02-01

223	10,568	36271	43868
papers	citations	51 h-index	91 g-index

226	226	226	10027
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HIV-1 Tat and cocaine coexposure impacts piRNAs to affect astrocyte energy metabolism. Epigenomics, 2022, 14, 261-278.	1.0	2
2	Very-Rapidly Dissolving Printlets of Isoniazid Manufactured by SLS 3D Printing: In Vitro and In Vivo Characterization. Molecular Pharmaceutics, 2022, 19, 2937-2949.	2.3	13
3	3D-printing of lopinavir printlets by selective laser sintering and quantification of crystalline fraction by XRPD-chemometric models. International Journal of Pharmaceutics, 2021, 592, 120059.	2.6	50
4	Preparation and characterization of dicarboxylic acids salt of aripiprazole with enhanced physicochemical properties. Pharmaceutical Development and Technology, 2021, 26, 455-463.	1.1	6
5	Development of stable amorphous solid dispersion and quantification of crystalline fraction of lopinavir by spectroscopic-chemometric methods. International Journal of Pharmaceutics, 2021, 602, 120657.	2.6	9
6	Ultra-long acting prodrug of dolutegravir and delivery system â€“ Physicochemical, pharmacokinetic and formulation characterizations. International Journal of Pharmaceutics, 2021, 607, 120889.	2.6	12
7	Development of Methamphetamine Abuseâ€“Deterrent Formulations Using Sucrose Acetate Isobutyrate. Journal of Pharmaceutical Sciences, 2020, 109, 1338-1346.	1.6	11
8	Studying effect of glyceryl palmitostearate amount, manufacturing method and stability on polymorphic transformation and dissolution of rifaximin tablets. International Journal of Pharmaceutics, 2020, 589, 119785.	2.6	6
9	Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration. International Journal of Pharmaceutics, 2020, 578, 119076.	2.6	26
10	Thermal Influence on Printlet Quality in the Selective Laser Sintering of Pharmaceutical Formulations. , 2020, , .		1
11	Univariate and Multivariate Models for Determination of Prasugrel Base in the Formulation of Prasugrel Hydrochloride Using XRPD Method. Journal of Pharmaceutical Sciences, 2019, 108, 3575-3581.	1.6	5
12	Blend of cellulose ester and enteric polymers for delayed and enteric coating of core tablets of hydrophilic and hydrophobic drugs. International Journal of Pharmaceutics, 2019, 567, 118462.	2.6	18
13	Chemometric Models for Quantification of Carbamazepine Anhydrous and Dihydrate Forms in the Formulation. Journal of Pharmaceutical Sciences, 2019, 108, 1211-1219.	1.6	16
14	Quantitative evaluation of the thallium binding of soluble and insoluble Prussian blue hexacyanoferrate analogs: A scientific comparison based on their critical quality attributes. International Journal of Pharmaceutics, 2019, 569, 118600.	2.6	10
15	Understanding the effects of formulation and process variables on the printlets quality manufactured by selective laser sintering 3D printing. International Journal of Pharmaceutics, 2019, 570, 118651.	2.6	72
16	Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion. AAPS PharmSciTech, 2019, 20, 230.	1.5	15
17	Development and Validation of a Discriminatory Dissolution Method for Rifaximin Products. Journal of Pharmaceutical Sciences, 2019, 108, 2112-2118.	1.6	9
18	Quality and In-Use Stability Comparison of Brand and Generics of Extended-Release Phenytoin Sodium Capsules. Journal of Pharmaceutical Sciences, 2019, 108, 1808-1817.	1.6	11

#	Article	IF	Citations
19	Quantitative estimation of phenytoin sodium disproportionation in the formulations using vibration spectroscopies and multivariate methodologies. International Journal of Pharmaceutics, 2018, 539, 65-74.	2.6	20
20	A headspace-gas chromatography method for isopropanol determination in warfarin sodium products as a measure of drug crystallinity. Acta Pharmaceutica, 2018, 68, 31-46.	0.9	3
21	Effect of processing parameters and controlled environment storage on the disproportionation and dissolution of extended-release capsule of phenytoin sodium. International Journal of Pharmaceutics, 2018, 550, 290-299.	2.6	21
22	A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews, 2017, 108, 39-50.	6.6	554
23	A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticlesâ€™ characteristics and efficacy of intracellular delivery. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 1657-1664.	1.9	59
24	In Vitro Drug Transfer Due to Drug Retention in Human Epidermis Pretreated with Application of Marketed Estradiol Transdermal Systems. AAPS PharmSciTech, 2017, 18, 2131-2140.	1.5	2
25	Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets. International Journal of Pharmaceutics, 2017, 517, 303-311.	2.6	28
26	Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigations. Clinical Pharmacology: Advances and Applications, 2017, Volume 9, 29-38.	0.8	19
27	Quality-by-Design (QbD) for Capsule Formulation and Process Development. , 2017, , 393-414.		0
28	Evaluation of the InÂVitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate. Journal of Pharmaceutical Sciences, 2016, 105, 864-875.	1.6	6
29	Critical Importance and Quality Evaluation of Drug Delivery Autoinjectors in the FDA-DOD Shelf Life Extension Program (SLEP). AAPS Journal, 2016, 18, 801-803.	2.2	3
30	Defining Patient Centric Pharmaceutical Drug Product Design. AAPS Journal, 2016, 18, 1047-1055.	2.2	61
31	Spectroscopic-Based Chemometric Models for Quantifying Low Levels of Solid-State Transitions in Extended Release Theophylline Formulations. Journal of Pharmaceutical Sciences, 2016, 105, 97-105.	1.6	14
32	Bupropion Hydrochloride. Profiles of Drug Substances, Excipients and Related Methodology, 2016, 41, 1-30.	3.5	25
33	Liposome Formation Using a Coaxial Turbulent Jet in Co-Flow. Pharmaceutical Research, 2016, 33, 404-416.	1.7	23
34	Risk based in vitro performance assessment of extended release abuse deterrent formulations. International Journal of Pharmaceutics, 2016, 500, 255-267.	2.6	28
35	Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations. International Journal of Pharmaceutics, 2016, 502, 138-150.	2.6	41
36	Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations. International Journal of Pharmaceutics, 2016, 499, 20-28.	2.6	13

#	Article	IF	Citations
37	Comparison of X-ray Powder Diffraction and Solid-State Nuclear Magnetic Resonance in Estimating Crystalline Fraction of Tacrolimus in Sustained-Release Amorphous Solid Dispersion and Development of Discriminating Dissolution Method. Journal of Pharmaceutical Sciences, 2015, 104, 1777-1786.	1.6	22
38	Chemometric Model Development and Comparison of Raman and 13C Solid-State Nuclear Magnetic Resonanceâ€"Chemometric Methods for Quantification of Crystalline/Amorphous Warfarin Sodium Fraction in the Formulations. Journal of Pharmaceutical Sciences, 2015, 104, 2550-2558.	1.6	33
39	Fermentanomics: Relating quality attributes of a monoclonal antibody to cell culture process variables and raw materials using multivariate data analysis. Biotechnology Progress, 2015, 31, 1586-1599.	1.3	30
40	Development and validation of in vitroâ€"in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems. Journal of Controlled Release, 2015, 210, 58-66.	4.8	61
41	Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations. International Journal of Pharmaceutics, 2015, 490, 341-350.	2.6	18
42	Bioreactor Process Parameter Screening Utilizing a Plackett-Burman Design for a Model Monoclonal Antibody. Journal of Pharmaceutical Sciences, 2015, 104, 1919-1928.	1.6	29
43	Evaluation of In-Use Stability of Anticoagulant Drug Products: Warfarin Sodium. Journal of Pharmaceutical Sciences, 2015, 104, 4232-4240.	1.6	19
44	Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin. International Journal of Pharmaceutics, 2015, 481, 104-113.	2.6	6
45	An Integrated Process Analytical Technology (PAT) Approach for Process Dynamics-Related Measurement Error Evaluation and Process Design Space Development of a Pharmaceutical Powder Blending Bed. Organic Process Research and Development, 2015, 19, 215-226.	1.3	14
46	Assessment of Recent Process Analytical Technology (PAT) Trends: A Multiauthor Review. Organic Process Research and Development, 2015, 19, 3-62.	1.3	329
47	Development and validation of X-ray diffraction method for quantitative determination of crystallinity in warfarin sodium products. International Journal of Pharmaceutics, 2015, 493, 1-6.	2.6	18
48	Kinetics of drug release from ointments: Role of transient-boundary layer. International Journal of Pharmaceutics, 2015, 494, 31-39.	2.6	37
49	Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments. International Journal of Pharmaceutics, 2015, 493, 412-425.	2.6	54
50	Integration of Near-Infrared Spectroscopy and Mechanistic Modeling for Predicting Film-Coating and Dissolution of Modified Release Tablets. Industrial & Engineering Chemistry Research, 2015, 54, 6012-6023.	1.8	11
51	Comparison of Univariate and Multivariate Models of 13C SSNMR and XRPD Techniques for Quantification of Nimodipine Polymorphs. AAPS PharmSciTech, 2015, 16, 1368-1376.	1.5	6
52	Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment. International Journal of Pharmaceutics, 2015, 495, 783-791.	2.6	33
53	Real time monitoring of bioreactor mAb IgG3 cell culture process dynamics via Fourier transform infrared spectroscopy: Implications for enabling cell culture process analytical technology. Frontiers of Chemical Science and Engineering, 2015, 9, 386-406.	2.3	15
54	Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product. International Journal of Pharmaceutics, 2015, 495, 19-30.	2.6	21

#	Article	IF	Citations
55	A long-term stability study of Prussian blue: A quality assessment of water content and cesium binding. Journal of Pharmaceutical and Biomedical Analysis, 2015, 103, 85-90.	1.4	10
56	An Integrated Process Analytical Technology (PAT) Approach for Pharmaceutical Crystallization Process Understanding to Ensure Product Quality and Safety: FDA Scientistâ€™s Perspective. Organic Process Research and Development, 2015, 19, 89-101.	1.3	34
57	A quantitative study of the effect of process parameters on key granule characteristics in a high shear wet granulation process involving a two component pharmaceutical blend. Advanced Powder Technology, 2015, 26, 315-322.	2.0	51
58	Characterization and selection of suitable grades of lactose as functional fillers for capsule filling: part 1. Drug Development and Industrial Pharmacy, 2015, 41, 1452-1463.	0.9	9
59	FDA Analysis of Atorvastatin Products Refutes Report of Methyl Ester Impurities. Therapeutic Innovation and Regulatory Science, 2014, 48, 554-556.	0.8	1
60	Stereomicroscopic Imaging Technique for the Quantification of Cold Flow in Drug-in-Adhesive Type of Transdermal Drug Delivery Systems. Journal of Pharmaceutical Sciences, 2014, 103, 1433-1442.	1.6	7
61	An Integrated Process Analytical Technology (PAT) Approach to Monitoring the Effect of Supercooling on Lyophilization Product and Process Parameters of Model Monoclonal Antibody Formulations. Journal of Pharmaceutical Sciences, 2014, 103, 2042-2052.	1.6	21
62	Analytical Methods for the Evaluation of Melamine Contamination. Journal of Pharmaceutical Sciences, 2014, 103, 539-544.	1.6	5
63	Evaluation of butyrateâ€induced production of a mannoseâ€6â€phosphorylated therapeutic enzyme using parallel bioreactors. Biotechnology and Applied Biochemistry, 2014, 61, 184-192.	1.4	9
64	A mechanistic population balance model for granulation processes: Effect of process and formulation parameters. Chemical Engineering Science, 2014, 107, 76-92.	1.9	40
65	Considerations for a Pediatric Biopharmaceutics Classification System (BCS): Application to Five Drugs. AAPS PharmSciTech, 2014, 15, 601-611.	1.5	35
66	Chemometric Methods for the Quantification of Crystalline Tacrolimus in Solid Dispersion by Powder Xâ€Ray Diffractrometry. Journal of Pharmaceutical Sciences, 2014, 103, 2819-2828.	1.6	27
67	Long-term stability study of Prussian blue â€“ A quality assessment of water content and thallium binding. International Journal of Pharmaceutics, 2014, 477, 122-127.	2.6	12
68	Integrated Process Analytical Technology Approach for Nucleation Induction Time Measurement and Nucleation Mechanism Assessment for a Dynamic Multicomponent Pharmaceutical Antisolvent Crystallization System. Industrial & Engineering Chemistry Research, 2014, 53, 1688-1701.	1.8	16
69	Quality by Design Approach for Understanding the Critical Quality Attributes of Cyclosporine Ophthalmic Emulsion. Molecular Pharmaceutics, 2014, 11, 787-799.	2.3	40
70	Development of performance matrix for generic product equivalence of acyclovir topical creams. International Journal of Pharmaceutics, 2014, 475, 110-122.	2.6	64
71	Cold flow of estradiol transdermal systems: Influence of drug loss on the in vitro flux and drug transfer across human epidermis. International Journal of Pharmaceutics, 2014, 477, 73-80.	2.6	8
72	Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics. International Journal of Pharmaceutics, 2014, 475, 462-470.	2.6	16

#	Article	IF	Citations
73	Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration. International Journal of Pharmaceutics, 2014, 473, 545-551.	2.6	15
74	Near-Infrared and Fourier Transform Infrared Chemometric Methods for the Quantification of Crystalline Tacrolimus from Sustained-Release Amorphous Solid Dispersion. Journal of Pharmaceutical Sciences, 2014, 103, 2376-2385.	1.6	18
75	United States Food and Drug Administration and Department of Defense Shelf-Life Extension Program of Pharmaceutical Products: Progress and Promise. Journal of Pharmaceutical Sciences, 2014, 103, 1331-1336.	1.6	24
76	Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: Iron sucrose. International Journal of Pharmaceutics, 2014, 464, 46-52.	2.6	13
77	Understanding Pharmaceutical Quality by Design. AAPS Journal, 2014, 16, 771-783.	2.2	846
78	A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms. AAPS Journal, 2013, 15, 1072-1081.	2.2	89
79	Development and Validation of a HPLC Method for Dissolution and Stability Assay of Liquid-Filled Cyclosporine Capsule Drug Products. AAPS PharmSciTech, 2013, 14, 959-967.	1.5	10
80	Formulation and transport properties of tenofovir loaded liposomes through Caco-2 cell model. Journal of Liposome Research, 2013, 23, 318-326.	1.5	22
81	Orally disintegrating tablet of novel salt of antiepileptic drug: Formulation strategy and evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1300-1309.	2.0	30
82	Impact of controlled ice nucleation on process performance and quality attributes of a lyophilized monoclonal antibody. International Journal of Pharmaceutics, 2013, 450, 70-78.	2.6	62
83	In Vitro Bioequivalence Approach for a Locally Acting Gastrointestinal Drug: Lanthanum Carbonate. Molecular Pharmaceutics, 2013, 10, 544-550.	2.3	16
84	Building better drugs: developing and regulating engineered therapeutic proteins. Trends in Pharmacological Sciences, 2013, 34, 534-548.	4.0	77
85	Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design Approach. Journal of Pharmaceutical Sciences, 2013, 102, 3748-3761.	1.6	63
86	Hunter screening design to understand the product variability of solid dispersion formulation of a peptide antibiotic. International Journal of Pharmaceutics, 2013, 456, 572-582.	2.6	9
87	Use of In Vitroâ€“In Vivo Correlation to Predict the Pharmacokinetics of Several Products Containing a BCS Class 1 Drug in Extended Release Matrices. Pharmaceutical Research, 2013, 30, 179-190.	1.7	17
88	Challenges of pediatric formulations: A FDA science perspective. International Journal of Pharmaceutics, 2013, 457, 346-348.	2.6	12
89	Assessing the impact of nimodipine devitrification in the ternary cosolvent system through quality by design approach. International Journal of Pharmaceutics, 2013, 455, 113-123.	2.6	23
90	Focused beam reflectance measurement to monitor nimodipine precipitation process. International Journal of Pharmaceutics, 2013, 456, 353-356.	2.6	6

#	Article	IF	Citations
91	Oseltamivir Phosphateâ€“Amberliteâ„¢ IRP 64 Ionic Complex for Taste Masking: Preparation and Chemometric Evaluation. Journal of Pharmaceutical Sciences, 2013, 102, 1800-1812.	1.6	15
92	Process Analytical Technology to Understand the Disintegration Behavior of Alendronate Sodium Tablets. Journal of Pharmaceutical Sciences, 2013, 102, 1513-1523.	1.6	9
93	Characterization of a Nonribosomal Peptide Antibiotic Solid Dispersion Formulation by Process Analytical Technologies Sensors. Journal of Pharmaceutical Sciences, 2013, 102, 4337-4346.	1.6	10
94	Chemometric Evaluation of Near Infrared, Fourier Transform Infrared, and Raman Spectroscopic Models for the Prediction of Nimodipine Polymorphs. Journal of Pharmaceutical Sciences, 2013, 102, 4024-4035.	1.6	23
95	Withdrawal of Generic Budeprion for Nonbioequivalence. New England Journal of Medicine, 2012, 367, 2463-2465.	13.9	39
96	Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin. Pharmaceutical Development and Technology, 2012, 17, 457-465.	1.1	29
97	Physicochemical Characterization of Complex Drug Substances: Evaluation of Structural Similarities and Differences of Protamine Sulfate from Various Sources. AAPS Journal, 2012, 14, 619-626.	2.2	24
98	Improvement of Physicochemical Properties of an Antiepileptic Drug by Salt Engineering. AAPS PharmSciTech, 2012, 13, 793-801.	1.5	35
99	Cholorpheniramine tannate complexes: Physicochemical, chemometric, and taste masking evaluation. International Journal of Pharmaceutics, 2012, 436, 582-592.	2.6	21
100	Quality by design: Impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody. International Journal of Pharmaceutics, 2012, 438, 167-175.	2.6	69
101	Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer. Pharmaceutical Development and Technology, 2012, 17, 521-540.	1.1	38
102	Spontaneous Carbonate Formation in an Amorphous, Amine-Rich, Polymeric Drug Substance: Sevelamer HCl Product Quality. Journal of Pharmaceutical Sciences, 2012, 101, 2681-2685.	1.6	2
103	Tannate complexes of antihistaminic drug: Sustained release and taste masking approaches. International Journal of Pharmaceutics, 2012, 422, 91-100.	2.6	24
104	Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis. International Journal of Pharmaceutics, 2012, 423, 341-350.	2.6	89
105	A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. International Journal of Pharmaceutics, 2012, 423, 543-553.	2.6	101
106	Predicting hydrophilic drug encapsulation inside unilamellar liposomes. International Journal of Pharmaceutics, 2012, 423, 410-418.	2.6	93
107	A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. International Journal of Pharmaceutics, 2012, 426, 211-218.	2.6	80
108	Application of quality by design to formulation and processing of protein liposomes. International Journal of Pharmaceutics, 2012, 434, 349-359.	2.6	54

#	Article	IF	Citations
109	Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate. Journal of Pharmaceutical and Biomedical Analysis, 2012, 62, 61-67.	1.4	108
110	THz spectroscopy: An emerging technology for pharmaceutical development and pharmaceutical Process Analytical Technology (PAT) applications. Journal of Molecular Structure, 2012, 1020, 112-120.	1.8	31
111	Chemometric Evaluation of Brompheniramineâ€"Tannate Complexes. Journal of Pharmaceutical Sciences, 2012, 101, 1450-1461.	1.6	3
112	Quality by design in formulation and process development for a freeze-dried, small molecule parenteral product: a case study. Pharmaceutical Development and Technology, 2011, 16, 549-576.	1.1	46
113	A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. International Journal of Pharmaceutics, 2011, 419, 52-59.	2.6	125
114	Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. European Journal of Pharmaceutical Sciences, 2011, 44, 93-102.	1.9	44
115	NIR Spectroscopy Applications in the Development of a Compacted Multiparticulate System for Modified Release. AAPS PharmSciTech, 2011, 12, 262-278.	1.5	29
116	A QbD Case Study: Bayesian Prediction of Lyophilization Cycle Parameters. AAPS PharmSciTech, 2011, 12, 442-448.	1.5	6
117	Physico-mechanical and Stability Evaluation of Carbamazepine Cocrystal with Nicotinamide. AAPS PharmSciTech, 2011, 12, 693-704.	1.5	107
118	Development and application of a validated HPLC method for the analysis of dissolution samples of levothyroxine sodium drug products. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 433-438.	1.4	34
119	Quality-by-Design: An Integrated Process Analytical Technology Approach to Determine the Nucleation and Growth Mechanisms During a Dynamic Pharmaceutical Coprecipitation Process. Journal of Pharmaceutical Sciences, 2011, 100, 1969-1986.	1.6	15
120	Quality-by-Design (QbD): An integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space developmentâ˜†. International Journal of Pharmaceutics, 2011, 405, 63-78.	2.6	92
121	Comparative stability study of unit-dose repackaged furosemide tablets. Clinical Research and Regulatory Affairs, 2011, 28, 38-48.	2.1	5
122	Formulation and Evaluation of a Protein-loaded Solid Dispersions by Non-destructive Methods. AAPS Journal, 2010, 12, 158-170.	2.2	21
123	Near-Infrared Investigations of Novel Anti-HIV Tenofovir Liposomes. AAPS Journal, 2010, 12, 202-214.	2.2	46
124	Online Monitoring of PLGA Microparticles Formation Using Lasentec Focused Beam Reflectance (FBRM) and Particle Video Microscope (PVM). AAPS Journal, 2010, 12, 254-262.	2.2	31
125	Influence of Formulation and Processing Factors on Stability of Levothyroxine Sodium Pentahydrate. AAPS PharmSciTech, 2010, 11, 818-825.	1.5	46
126	Tablet Splitting of a Narrow Therapeutic Index Drug: A Case with Levothyroxine Sodium. AAPS PharmSciTech, 2010, 11, 1359-1367.	1.5	64

#	Article	IF	Citations
127	Thermodynamic stability assessment of a colloidal iron drug product: Sodium ferric gluconate**This scientific contribution is intended to support regulatory policy development. The views presented in this article have not been adopted as regulatory policies by the Food and Drug Administration at this time.. Journal of Pharmaceutical Sciences, 2010, 99, 142-153.	1.6	20
128	Qualityâ€byâ€Design (QbD): An Integrated Process Analytical Technology (PAT) Approach for Realâ€Time Monitoring and Mapping the State of a Pharmaceutical Coprecipitation Process. Journal of Pharmaceutical Sciences, 2010, 99, 1516-1534.	1.6	42
129	Spectral and Spatial Characterization of Protein Loaded PLGA Nanoparticles. Journal of Pharmaceutical Sciences, 2010, 99, 1180-1192.	1.6	12
130	Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 1108-1112.	1.4	38
131	Comparative stability of repackaged metoprolol tartrate tablets. International Journal of Pharmaceutics, 2010, 385, 92-97.	2.6	13
132	Understanding the quality of protein loaded PLGA nanoparticles variability by Plackettâ€“Burman design. International Journal of Pharmaceutics, 2010, 389, 186-194.	2.6	138
133	Risperidone solid dispersion for orally disintegrating tablet: Its formulation design and non-destructive methods of evaluation. International Journal of Pharmaceutics, 2010, 400, 49-58.	2.6	65
134	Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets. International Journal of Pharmaceutics, 2010, 401, 25-31.	2.6	29
135	Use of Hydrogenophaga pseudoflava Penetration To Quantitatively Assess the Impact of Filtration Parameters for 0.2-Micrometer-Pore-Size Filters. Applied and Environmental Microbiology, 2010, 76, 695-700.	1.4	11
136	Non-destructive methods of characterization of risperidone solid lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 127-137.	2.0	149
137	Development and application of a validated stability-indicating Ultra-Performance Liquid Chromatography (UPLC) method for the determination of dantrolene and its related impurities. Clinical Research and Regulatory Affairs, 2010, 27, 21-29.	2.1	7
138	Stability of gabapentin 300-mg capsules repackaged in unit dose containers. American Journal of Health-System Pharmacy, 2009, 66, 1376-1380.	0.5	15
139	Robust Calibration Design in the Pharmaceutical Quantitative Measurements with Near-Infrared (NIR) Spectroscopy: Avoiding the Chemometric Pitfalls. Journal of Pharmaceutical Sciences, 2009, 98, 1155-1166.	1.6	40
140	Quality-By-Design (QbD): An Integrated Approach for Evaluation of Powder Blending Process Kinetics and Determination of Powder Blending End-point. Journal of Pharmaceutical Sciences, 2009, 98, 2784-2798.	1.6	54
141	Real-time on-line blend uniformity monitoring using near-infrared reflectance spectrometry: A noninvasive off-line calibration approach. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 48-54.	1.4	68
142	Quality-by-Design (QbD): An integrated multivariate approach for the component quantification in powder blendsâ†. International Journal of Pharmaceutics, 2009, 372, 39-48.	2.6	81
143	Disintegration of Highly Soluble Immediate Release Tablets: A Surrogate for Dissolution. AAPS PharmSciTech, 2009, 10, 495-499.	1.5	33
144	Difference in the Lubrication Efficiency of Bovine and Vegetable-Derived Magnesium Stearate During Tabletting. AAPS PharmSciTech, 2009, 10, 500-504.	1.5	10

#	Article	IF	Citations
145	Evaluation of Transmission and Reflection Modalities for Measuring Content Uniformity of Pharmaceutical Tablets with Near-Infrared Spectroscopy. Applied Spectroscopy, 2009, 63, 33-47.	1.2	16
146	Complexation of risperidone with a taste-masking resin: Novel application of near infra-red and chemical imaging to evaluate complexes. Pharmaceutical Development and Technology, 2009, 14, 409-421.	1.1	26
147	Process Analytical Technology (PAT): Quantification Approaches in Terahertz Spectroscopy for Pharmaceutical Application. Journal of Pharmaceutical Sciences, 2008, 97, 970-984.	1.6	54
148	Process Analytical Technology: Nondestructive Evaluation of Cyclosporine A and Phospholipid Solid Dispersions by Near Infrared Spectroscopy and Imaging. Journal of Pharmaceutical Sciences, 2008, 97, 3388-3399.	1.6	16
149	Quality-by-Design (QbD): Effects of Testing Parameters and Formulation Variables on the Segregation Tendency of Pharmaceutical Powder Measured by the ASTM D 6940-04 Segregation Tester. Journal of Pharmaceutical Sciences, 2008, 97, 4485-4497.	1.6	44
150	Functionality of magnesium stearate derived from bovine and vegetable sources: Dry granulated tablets. Journal of Pharmaceutical Sciences, 2008, 97, 5328-5340.	1.6	11
151	Development and application of a validated HPLC method for the analysis of dissolution samples of gabapentin drug products. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 181-186.	1.4	32
152	Quantitative determination of cesium binding to ferric hexacyanoferrate: Prussian blue. Journal of Pharmaceutical and Biomedical Analysis, 2008, 47, 114-125.	1.4	119
153	Comparison of the stability of split and intact gabapentin tablets. International Journal of Pharmaceutics, 2008, 350, 65-69.	2.6	19
154	Molecular weight determination for colloidal iron by Taguchi optimized validated gel permeation chromatographyâ˜†. International Journal of Pharmaceutics, 2008, 353, 21-27.	2.6	12
155	Quantitative determination of thallium binding to ferric hexacyanoferrate: Prussian blueâ˜†. International Journal of Pharmaceutics, 2008, 353, 187-194.	2.6	42
156	Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. International Journal of Pharmaceutics, 2008, 360, 77-82.	2.6	32
157	Effect of Ethanol on Opioid Drug Permeability Through Caco-2 Cell Monolayers. AAPS Journal, 2008, 10, 360-362.	2.2	18
158	Comparative Evaluation of Flow for Pharmaceutical Powders and Granules. AAPS PharmSciTech, 2008, 9, 250-258.	1.5	326
159	Stability of ranitidine syrup repackaged in unit-dose containers. American Journal of Health-System Pharmacy, 2008, 65, 325-329.	0.5	10
160	Optimization and In Vivo Evaluation of an Oral Dual Controlled-Release Tablet Dosage Form of Insulin and Duck Ovomucoid. Pharmaceutical Development and Technology, 2008, 13, 291-298.	1.1	3
161	PROCESS CONTROL PERSPECTIVE FOR PROCESS ANALYTICAL TECHNOLOGY: INTEGRATION OF CHEMICAL ENGINEERING PRACTICE INTO SEMICONDUCTOR AND PHARMACEUTICAL INDUSTRIES. Chemical Engineering Communications, 2007, 194, 760-779.	1.5	49
162	Controlled Release Multiparticulate Beads Coated with Starch Acetate: Material Characterization, and Identification of Critical Formulation and Process Variables. Pharmaceutical Development and Technology, 2007, 12, 307-320.	1.1	12

#	Article	IF	Citations
163	Quality by Design: Understanding The Product Variability of a Self-Nanoemulsified Drug Delivery System of Cyclosporine A. Journal of Pharmaceutical Sciences, 2007, 96, 2409-2423.	1.6	29
164	Process Analytical Technology: Chemometric Analysis of Raman and Near Infra-Red Spectroscopic Data for Predicting Physical Properties of Extended Release Matrix Tablets. Journal of Pharmaceutical Sciences, 2007, 96, 1356-1365.	1.6	68
165	Drug product characterization by Macropixel Analysis of chemical images. Journal of Pharmaceutical Sciences, 2007, 96, 3390-3401.	1.6	32
166	Quality by design: Understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Boxâ€“Behnken design and desirability function. International Journal of Pharmaceutics, 2007, 332, 55-63.	2.6	118
167	Quality by design: Characterization of self-nano-emulsified drug delivery systems (SNEDDs) using ultrasonic resonator technology. International Journal of Pharmaceutics, 2007, 341, 189-194.	2.6	54
168	Process analytical technology (PAT): Effects of instrumental and compositional variables on terahertz spectral data quality to characterize pharmaceutical materials and tablets. International Journal of Pharmaceutics, 2007, 343, 148-158.	2.6	56
169	Development and application of a validated HPLC method for the determination of gabapentin and its major degradation impurity in drug products. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1647-1653.	1.4	47
170	Response Surface Methodology to Obtain Î²-Estradiol Biodegradable Microspheres for Long-Term Therapy of Osteoporosis. Pharmaceutical Development and Technology, 2006, 11, 377-387.	1.1	7
171	Development of a Validated Stability Indicating HPLC Method for Ranitidine Hydrochloride Syrup. Clinical Research and Regulatory Affairs, 2006, 23, 35-51.	2.1	7
172	Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters. International Journal of Pharmaceutics, 2006, 315, 110-121.	2.6	98
173	Preparation and characterization of genistein containing poly(ethylene glycol) microparticles. Journal of Applied Polymer Science, 2006, 101, 2070-2078.	1.3	43
174	Optimization and characterization of controlled release multi-particulate beads coated with starch acetate. International Journal of Pharmaceutics, 2005, 294, 89-101.	2.6	35
175	Biodegradable Microparticulates of Beta-Estradiol: Preparation and In Vitro Characterization. Drug Development and Industrial Pharmacy, 2005, 31, 803-811.	0.9	12
176	An Enteric Dualâ€Controlled Gastrointestinal Therapeutic System of Salmon Calcitoninâ€‡: Preparation, Characterization, and Preclinical Bioavailability in Rats. Clinical Research and Regulatory Affairs, 2004, 21, 81-96.	2.1	3
177	A Dual Controlled Gastrointestinal Therapeutic System of Salmon Calcitonin. II. Screening of Process and Formulation Variables. Clinical Research and Regulatory Affairs, 2004, 21, 231-238.	2.1	4
178	Absorption enhancers in pulmonary protein delivery. Journal of Controlled Release, 2004, 94, 15-24.	4.8	149
179	Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery. Journal of Pharmaceutical Sciences, 2004, 93, 392-406.	1.6	24
180	Chain Length-Dependent Effects of Alkylmaltosides on Nasal Absorption of Enoxaparin. Journal of Pharmaceutical Sciences, 2004, 93, 675-683.	1.6	31

#	Article	IF	Citations
181	Cytotoxicity evaluation of enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon calcitonin. Journal of Pharmaceutical Sciences, 2004, 93, 1070-1082.	1.6	25
182	Evaluation of cytotoxicity of oils used in coenzyme Q10 Self-Emulsifying Drug Delivery Systems (SEDDS). International Journal of Pharmaceutics, 2004, 273, 63-73.	2.6	57
183	Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. International Journal of Pharmaceutics, 2004, 279, 3-7.	2.6	17
184	Preparation and in vitro characterization of self-nanoemulsified drug delivery system (SNEDDS) of all-trans-retinol acetate. International Journal of Pharmaceutics, 2004, 285, 109-119.	2.6	102
185	Development of a HPLC method for the determination of cyclosporin-A in rat blood and plasma using naproxen as an internal standard. Journal of Pharmaceutical and Biomedical Analysis, 2003, 31, 1101-1107.	1.4	10
186	Salbutamol Sulfate Suppositories: Influence of Formulation on Physical Parameters and Stability. Pharmaceutical Development and Technology, 2003, 8, 21-30.	1.1	11
187	Bioavailability Assessment of Oral Coenzyme Q10 Formulations in Dogs. Drug Development and Industrial Pharmacy, 2002, 28, 1195-1200.	0.9	25
188	Targeting to macrophages: role of physicochemical properties of particulate carriersâ€"liposomes and microspheresâ€"on the phagocytosis by macrophages. Journal of Controlled Release, 2002, 79, 29-40.	4.8	498
189	Preparation and characterization of a customized cellulose acetate butyrate dispersion for controlled drug delivery. Journal of Pharmaceutical Sciences, 2002, 91, 1512-1522.	1.6	19
190	Optimization and characterization of controlled release multi-particulate beads formulated with a customized cellulose acetate butyrate dispersion. International Journal of Pharmaceutics, 2002, 234, 179-193.	2.6	49
191	Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology: effect of formulation ingredients. International Journal of Pharmaceutics, 2002, 240, 103-114.	2.6	111
192	Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. International Journal of Pharmaceutics, 2002, 235, 247-265.	2.6	223
193	Response surface methodology to obtain naproxen controlled release tablets from its microspheres with Eudragit L100-55. Journal of Microencapsulation, 2001, 18, 651-662.	1.2	22
194	Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. International Journal of Pharmaceutics, 2001, 212, 233-246.	2.6	506
195	Polymethyacrylate based microparticulates of insulin for oral delivery: Preparation and in vitro dissolution stability in the presence of enzyme inhibitors. International Journal of Pharmaceutics, 2001, 225, 31-39.	2.6	47
196	Design, in vitro stability, and ocular hypotensive activity of t-butalone chemical delivery systems. Journal of Pharmaceutical Sciences, 2001, 90, 1026-1033.	1.6	5
197	Aqueous-Based Cellulose Acetate Butyrate Dispersion: Screening of Process and Formulation Variables to Obtain Verapamil HCl-Controlled Release Beads. Particulate Science and Technology, 2001, 19, 131-144.	1.1	5
198	Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: evaluation of main effects of several formulation variables. International Journal of Pharmaceutics, 2000, 193, 147-156.	2.6	30

#	Article	IF	Citations
199	Stability characterization of controlled release coprecipitates and solid dispersions. Journal of Controlled Release, 2000, 63, 1-6.	4.8	25
200	Permeability of Chemical Delivery Systems Across Rabbit Corneal (SIRC) Cell Line and Isolated Corneas: A Comparative Study. Pharmaceutical Development and Technology, 2000, 5, 409-416.	1.1	35
201	Chemical Delivery Systems: Evaluation of Physicochemical Properties and Enzymatic Stability of Phenylephrone Derivatives. Pharmaceutical Development and Technology, 1999, 4, 189-198.	1.1	7
202	Transbuccal permeation of a nucleoside analog, dideoxycytidine: effects of menthol as a permeation enhancer. International Journal of Pharmaceutics, 1999, 192, 139-146.	2.6	51
203	Permeability characteristics of novel mydriatic agents using an in vitro cell culture model that utilizes sirc rabbit corneal cells. Journal of Pharmaceutical Sciences, 1999, 88, 180-184.	1.6	37
204	Stability and Bioequivalence Studies of Two Marketed Formulations of Coenzyme Q10 in Beagle Dogs.. Chemical and Pharmaceutical Bulletin, 1999, 47, 1024-1028.	0.6	23
205	Racemate and Enantiomers of Ketoprofen: Phase Diagram, Thermodynamic Studies, Skin Permeability, and Use of Chiral Permeation Enhancers. Journal of Pharmaceutical Sciences, 1998, 87, 833-840.	1.6	63
206	Aqueous based polymeric dispersion: Plackettâ€“Burman design for screening of formulation variables of Atenolol Gastrointestinal Therapeutic System. Pharmaceutica Acta Helvetiae, 1998, 73, 105-112.	1.2	37
207	Solid-state stability assessment of controlled release tablets containing CarbopolÂ® 971P. Journal of Controlled Release, 1998, 54, 87-93.	4.8	19
208	Aqueous-based polymeric dispersion: preparation and characterization of cellulose acetate pseudolatex. International Journal of Pharmaceutics, 1998, 165, 175-189.	2.6	14
209	A simplified chromatographic method for quantitative determination of coenzyme Q10 in dog plasma. Journal of Pharmaceutical and Biomedical Analysis, 1998, 16, 1037-1040.	1.4	19
210	Aqueous-Based Polymeric Dispersion: Face-Centered Cubic Design for the Development of Atenolol Gastrointestinal Therapeutic System. Pharmaceutical Development and Technology, 1998, 3, 423-432.	1.1	14
211	Comparative Evaluation of the Severity of Gastric Ulceration by Solid Dispersions and Coprecipitates of Indomethacin. Journal of Drug Targeting, 1997, 4, 297-301.	2.1	2
212	Atenolol gastrointestinal therapeutic system: optimization of formulation variables using response surface methodology. Journal of Controlled Release, 1997, 45, 121-130.	4.8	43
213	Effect of Menthol and Related Terpenes on the Percutaneous Absorption of Propranolol across Excised Hairless Mouse Skin. Journal of Pharmaceutical Sciences, 1997, 86, 1369-1373.	1.6	113
214	Permeability of a Soft Steroid, Loteprednol Etabonate, Through an Excised Rabbit Cornea. Journal of Ocular Pharmacology and Therapeutics, 1996, 12, 159-167.	0.6	18
215	Box-behnken design for the optimization of formulation variables of indomethacin coprecipitates with polymer mixtures. International Journal of Pharmaceutics, 1996, 131, 9-17.	2.6	59
216	Optimization and characterization of controlled release pellets coated with an experimental latex: II. Cationic drug. International Journal of Pharmaceutics, 1996, 141, 179-195.	2.6	15

#	Article	IF	Citations
217	Optimization and characterization of controlled release pellets coated with an experimental latex: I. Anionic drug. International Journal of Pharmaceutics, 1995, 125, 243-255.	2.6	63
218	Controlled release coprecipitates: formulation considerations. Journal of Controlled Release, 1995, 37, 131-141.	4.8	26
219	Morpholinoalkyl Ester Prodrugs of Diclofenac: Synthesis,In VitroandIn VivoEvaluation. Journal of Pharmaceutical Sciences, 1994, 83, 644-648.	1.6	50
220	Optimization of process variables for the preparation of ibuprofen coprecipitates with eudragit S100. International Journal of Pharmaceutics, 1994, 102, 185-192.	2.6	27
221	Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. Pharmaceutical Research, 1993, 10, 1191-1199.	1.7	51
222	Physical Characterization and Dissolution Properties of Ibuprofen:Eudragit Coprecipitates. Journal of Pharmaceutical Sciences, 1991, 80, 799-804.	1.6	84
223	Evaluation of carrier capacity and release characteristics for poly(butyl 2-cyanoacrylate) nanoparticles. International Journal of Pharmaceutics, 1986, 30, 17-28.	2.6	77